Literature DB >> 18645067

Arginine vasopressin antagonists for the treatment of heart failure and hyponatremia.

John J Finley1, Marvin A Konstam, James E Udelson.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18645067     DOI： 10.1161/CIRCULATIONAHA.108.765289

Source DB:  PubMed          Journal:  Circulation        ISSN： 0009-7322            Impact factor:   29.690


× No keyword cloud information.
  21 in total

1.  Enhanced NMDA receptor-mediated intracellular calcium signaling in magnocellular neurosecretory neurons in heart failure rats.

Authors:  Javier E Stern; Evgeniy S Potapenko
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2013-06-19       Impact factor: 3.619

2.  Predictability of tricuspid annular plane systolic excursion for the effectiveness of tolvaptan in patients with heart failure.

Authors:  Toru Niwa; Katsuhisa Waseda; Tomofumi Mizuno; Yusuke Nakano; Kentaro Mukai; Hirokazu Wakabayashi; Atsushi Watanabe; Hirohiko Ando; Hiroaki Takashima; Tetsuya Amano
Journal:  J Echocardiogr       Date:  2017-02-13

Review 3.  Targeting hyponatremia and hemodynamics in acute decompensated heart failure: is there a role for vasopressin antagonists?

Authors:  Gregory Valania; Manmeet Singh; Mara T Slawsky
Journal:  Curr Heart Fail Rep       Date:  2011-09

Review 4.  Novel therapeutic targets for the treatment of heart failure.

Authors:  Juan Tamargo; José López-Sendón
Journal:  Nat Rev Drug Discov       Date:  2011-06-24       Impact factor: 84.694

Review 5.  Medical therapy for acute decompensated heart failure: what recent clinical trials have taught us about diuretics and vasodilators.

Authors:  Catherine Marti; Robert Cole; Andreas Kalogeropoulos; Vasiliki Georgiopoulou; Javed Butler
Journal:  Curr Heart Fail Rep       Date:  2012-03

6.  Association of arginine vasopressin levels with outcomes and the effect of V2 blockade in patients hospitalized for heart failure with reduced ejection fraction: insights from the EVEREST trial.

Authors:  David E Lanfear; Hani N Sabbah; Steven R Goldsmith; Stephen J Greene; Andrew P Ambrosy; Angela J Fought; Mary J Kwasny; Karl Swedberg; Clyde W Yancy; Marvin A Konstam; Aldo P Maggioni; Faiez Zannad; Mihai Gheorghiade
Journal:  Circ Heart Fail       Date:  2012-12-12       Impact factor: 8.790

Review 7.  Pathophysiology and the cardiorenal connection in heart failure. Circulating hormones: biomarkers or mediators.

Authors:  Alessia Buglioni; John C Burnett
Journal:  Clin Chim Acta       Date:  2014-10-23       Impact factor: 3.786

Review 8.  Acute decompensated heart failure: contemporary medical management.

Authors:  Susan M Joseph; Ari M Cedars; Gregory A Ewald; Edward M Geltman; Douglas L Mann
Journal:  Tex Heart Inst J       Date:  2009

Review 9.  Arginine vasopressin receptor signaling and functional outcomes in heart failure.

Authors:  Melissa A Wasilewski; Valerie D Myers; Fabio A Recchia; Arthur M Feldman; Douglas G Tilley
Journal:  Cell Signal       Date:  2015-07-30       Impact factor: 4.315

Review 10.  Vasopressin receptor antagonists for the treatment of heart failure: a systematic review and meta-analysis of randomized controlled trials.

Authors:  Ionut Nistor; Iris Bararu; Maria-Cristina Apavaloaie; Luminita Voroneanu; Mihaela-Dora Donciu; Mehmet Kanbay; Evi V Nagler; Adrian Covic
Journal:  Int Urol Nephrol       Date:  2014-10-04       Impact factor: 2.370
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.